IL317573A - Combination therapy for treating cancer - Google Patents

Combination therapy for treating cancer

Info

Publication number
IL317573A
IL317573A IL317573A IL31757324A IL317573A IL 317573 A IL317573 A IL 317573A IL 317573 A IL317573 A IL 317573A IL 31757324 A IL31757324 A IL 31757324A IL 317573 A IL317573 A IL 317573A
Authority
IL
Israel
Prior art keywords
combination therapy
treating cancer
cancer
treating
therapy
Prior art date
Application number
IL317573A
Other languages
Hebrew (he)
Inventor
Alan Yin Kai Lau
Elisabetta Leo
Giuditta Illuzzi
Original Assignee
Astrazeneca Ab
Alan Yin Kai Lau
Elisabetta Leo
Giuditta Illuzzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Alan Yin Kai Lau, Elisabetta Leo, Giuditta Illuzzi filed Critical Astrazeneca Ab
Publication of IL317573A publication Critical patent/IL317573A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL317573A 2022-06-15 2023-06-14 Combination therapy for treating cancer IL317573A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263366407P 2022-06-15 2022-06-15
US202263386966P 2022-12-12 2022-12-12
PCT/EP2023/066018 WO2023242302A1 (en) 2022-06-15 2023-06-14 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
IL317573A true IL317573A (en) 2025-02-01

Family

ID=86903948

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317573A IL317573A (en) 2022-06-15 2023-06-14 Combination therapy for treating cancer

Country Status (11)

Country Link
US (1) US20250352539A1 (en)
EP (1) EP4539847A1 (en)
JP (1) JP2025522390A (en)
KR (1) KR20250023494A (en)
CN (1) CN119317434A (en)
AU (1) AU2023290506A1 (en)
CA (1) CA3258066A1 (en)
IL (1) IL317573A (en)
MX (1) MX2024014940A (en)
TW (1) TW202415376A (en)
WO (1) WO2023242302A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (en) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutations of the 17q associated ovarian and breast cancer susceptibility gene
PL3354650T3 (en) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
TWI499418B (en) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl Isoquinolin-1(2h)-one derivatives
WO2011006794A1 (en) 2009-07-14 2011-01-20 Nerviano Medical Sciences S.R.L. 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors
WO2011006803A1 (en) 2009-07-14 2011-01-20 Nerviano Medical Sciences S.R.L. 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl compounds for use as ATR inhibitors
WO2013014038A1 (en) 2011-07-26 2013-01-31 Nerviano Medical Sciences S.R.L. 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
EP2788328B1 (en) 2011-11-25 2018-01-31 Nerviano Medical Sciences S.r.l. 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors
EA028506B1 (en) 2012-10-26 2017-11-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors, process for the preparation and use thereof
TWI656121B (en) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(morpholin-4-yl)-1,7-naphthyridine
BR112017007708B8 (en) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Macrocyclic compound and pharmaceutical composition
GB201800733D0 (en) * 2018-01-17 2018-02-28 Cambridge Entpr Ltd Cancer
CA3122182A1 (en) 2018-12-18 2020-06-25 Astrazeneca Ab Pharmaceutical process and intermediates
TWI837403B (en) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 Chemical compounds
RS66523B1 (en) 2019-08-06 2025-03-31 Wuxi Biocity Biopharmaceutics Co Ltd Crystalline forms of an atr inhibitor and use thereof
IL293810A (en) * 2019-12-11 2022-08-01 Repare Therapeutics Inc Use of atr inhibitors in combination with parp inhibitors
CN113797341B (en) * 2020-06-12 2022-11-11 周凌云 Application of ATR (attenuated total tumor) inhibitor and PARP1 inhibitor in preparation of medicines for treating hepatitis B related liver cancer
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
JP2024522736A (en) * 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド Use of ATR inhibitors in combination with PARP inhibitors for the treatment of cancer - Patents.com

Also Published As

Publication number Publication date
CN119317434A (en) 2025-01-14
AU2023290506A1 (en) 2025-01-23
MX2024014940A (en) 2025-01-09
KR20250023494A (en) 2025-02-18
US20250352539A1 (en) 2025-11-20
WO2023242302A1 (en) 2023-12-21
EP4539847A1 (en) 2025-04-23
CA3258066A1 (en) 2023-12-21
TW202415376A (en) 2024-04-16
JP2025522390A (en) 2025-07-15

Similar Documents

Publication Publication Date Title
IL304275A (en) Methods for treating cancer
HUE069249T2 (en) Combination therapy for treating cancer
IL307964A (en) Combination therapy for cancer treatment
IL320332A (en) Methods for treating cancer
ZA202310076B (en) Combination therapies for treating cancer
IL319513A (en) Compounds for treating cancer
IL316016A (en) Combination therapy for treating cancer
IL316017A (en) Combination therapy for treating cancer
EP3813854A4 (en) In vivo controlled combination therapy for treatment of cancer
IL316019A (en) Combination therapy for treating cancer
GB202301902D0 (en) Combination therapy for cancer
IL288178A (en) Gmci and ddri combination therapy for treating cancer
GB202218395D0 (en) Cancer therapy
EP4313029A4 (en) Combination therapy for cancer treatment
IL305777A (en) Therapeutic combination for treating cancer
IL326216A (en) Combination therapy for prostate cancer
CA3272243A1 (en) Combination therapy for treating cancer
HK40121856A (en) Combination therapy for treating cancer
HK40121918A (en) Combination therapy for treating cancer
GB202208893D0 (en) Combination therapy for cancer
IL317472A (en) Eravacycline for treating cancer
HK40107047A (en) Therapeutic combination for treating cancer
IL320482A (en) Combination therapy for the treatment of cancer
GB202508616D0 (en) Combination therapy for cancer
CA3302004A1 (en) Combination therapy for treating prostate cancer